Gefurulimab Meets Primary and Secondary Endpoints...
Category : Clinical Trial Update 3 November 2025Positive topline results from the global PREVAIL Phase III trial showed that gefurulimab achieved bo...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
GC Biopharma Publishes Phase 2 Results of World’s...
Category : Clinical Trial Update 3 November 2025Study demonstrates strong immunogenicity and favorable safety profile for BARYTHRAX inj. (GC1109)...
Otsuka Pharmaceutical Secures Exclusive Rights to...
Category : Licensing/Collaboration Deal 3 November 2025License agreement covers innovative gene therapy 4D-150 for neovascular age-related macular degenera...
REGENXBIO Completes Enrollment in Pivotal Duchenne...
Category : Clinical Trial Update 1 November 2025REGENXBIO Inc. has reached two major milestones in its Duchenne muscular dystrophy (DMD) program &md...
Shanghai Zhimeng Begins Phase 2/3 Trial of Novel P...
Category : Clinical Trial Update 1 November 2025Shanghai Zhimeng Biopharma Inc. has officially launched the Phase 2/3 clinical trial of its new-gene...
Latest Newsletter Post
-
Otsuka Pharmaceutical Secures Exclu..
3 November 2025
-
GC Biopharma Publishes Phase 2 Resu..
3 November 2025
-
Gefurulimab Meets Primary and Secon..
3 November 2025
-
Vesper Bio Reports Promising Phase..
1 November 2025
-
Shanghai Zhimeng Begins Phase 2/3 T..
1 November 2025
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com